预约演示

更新于：2025-05-07

Opsoclonus-Myoclonus Syndrome

视性眼肌阵挛综合征

更新于：2025-05-07

基本信息

别名

Ataxo-opso-myoclonus syndrome、Dancing Eyes Dancing Feet Syndrome、Dancing Eyes, Dancing Feet Syndrome

+ [44]

简介

A neurological condition that is characterized by uncontrolled rapid irregular movements of the eye (OPSOCLONUS) and the muscle (MYOCLONUS) causing unsteady, trembling gait. It is also known as dancing eyes-dancing feet syndrome and is often associated with neoplasms, viral infections, or autoimmune disorders involving the nervous system.

关联

项与视性眼肌阵挛综合征相关的药物

Rituximab

利妥昔单抗

靶点

CD20

作用机制

CD20抑制剂 [+3]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1997-11-26

Cyclophosphamide

环磷酰胺

靶点

DNA

作用机制

DNA抑制剂

在研机构

Shionogi & Co., Ltd. [+36]

原研机构

Baxter International, Inc.

在研适应症

移植物抗宿主病 [+238]

非在研适应症

急性红细胞白血病 [+207]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1959-11-16

项与视性眼肌阵挛综合征相关的临床试验

NL-OMON47850

/ SuspendedN/A

The evaluation of the cerebellar symptoms in patients with opsoclonus myoclonus syndrome diagnosed and treated at the Sophia*s Children*s hospital - Evaluation of long term sequelae and treatment outcomes in OMS

开始日期2018-02-01

申办/合作机构

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

DRKS00007547

/ RecruitingN/AIIT

Survey on the long-term outcome of opsomyoclonus-syndrome - OMS Survey

开始日期2015-02-01

申办/合作机构-

NCT01868269

/ Completed临床3期IIT

Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome

The OMS/DES study is a multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome.
This trial brought on the way by specialists of the EPNS (European Paediatric Neurology Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).
This protocol will investigate an escalating treatment schedule starting with a corticosteroid standard treatment with dexamethasone pulses (first step), which is followed, if response has been inadequate after 3 months of treatment, by the addition of CP (second step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES severity.

开始日期2013-04-18

申办/合作机构

Institut Curie

100 项与视性眼肌阵挛综合征相关的临床结果

登录后查看更多信息

100 项与视性眼肌阵挛综合征相关的转化医学

登录后查看更多信息

0 项与视性眼肌阵挛综合征相关的专利（医药）

登录后查看更多信息

1,183

项与视性眼肌阵挛综合征相关的文献（医药）

2025-06-01·Journal of Stomatology, Oral and Maxillofacial Surgery

Surgically treated chronic maxillary sinusitis: Does the odontogenic etiology alone or in combination with a fungus ball matter?

Article

作者: Scolozzi, Paolo ; Daskalou, Dimitrios ; Hsieh, Julien Wen ; Donna, Edouard Di ; Landis, Basile Nicolas ; Aymon, Romain ; Perez, Alexandre

PURPOSETo determine whether odontogenic maxillary sinusitis, either alone (OMSw/oFB) or in combination with fungus ball (OMSwFB), is associated with specific clinical characteristics and treatment outcomes compared to non-odontogenic maxillary sinusitis.MATERIALS AND METHODSA retrospective cohort study was performed on patients who underwent surgical treatment for chronic maxillary sinusitis between 2013 and 2021. OMSw/oFB and OMSwFB patients, were selected as the study group, while patients diagnosed with non-odontogenic maxillary sinusitis (non-OMS) were enrolled as the control group. Predictor variables were OMSw/oFB and OMSwFB. Outcomes were clinical presentation, postoperative complications, and treatment outcome. Descriptive, bivariate, and multiple logistic regression statistics were calculated, and the significance level was set at P ≤ 0.05.RESULTSThe sample included 200 patients with a mean age of 49.6 ± 20.1 years and 57.5 % were men. Of the 200 patients, 123 (61.5 %) had non-OMS, 55 (27.5 %) had OMSw/oFB, and 22 (11 %) had OMSwFB. Multivariate analysis showed that OMSw/oFB was associated with more successful treatment rates (OR = 8.19, p < 0.01), whereas OMSwFB was associated with a less favorable outcome (OR = 0.27, p = 0.03). Age was associated with an unfavorable outcome in both OMS groups (OR: 0.98, p = 0.03 and p = 0.03, respectively), but no significant associations with other outcomes were found.CONCLUSIONThis study suggests that OMSwFB is a recalcitrant form of OMS associated with a higher risk of persistent symptoms and less favorable outcome. These patients should be informed about the challenging nature of the disease and closely monitored.

2025-04-02·The American Journal of Tropical Medicine and Hygiene

Opsoclonus Myoclonus Ataxia Syndrome: An Atypical Presentation of Tuberculous Meningitis

Article

作者: Sharawat, Indar Kumar ; Sopanam, Suthiraj ; Panda, Prateek Kumar ; Gupta, Diksha ; Palayullakandi, Achanya

ABSTRACT.Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare neuroinflammatory disorder that is typically associated with paraneoplastic and postinfectious processes. Opsoclonus myoclonus ataxia syndrome has not been previously reported in association with tuberculous meningitis (TBM). This report presents a unique case in which TBM manifested as OMAS, highlighting the complex interplay between tuberculosis and autoimmune neurological conditions. A 1.5-year-old previously healthy girl, presented with acute-onset jerky movements, opsoclonus, irritability, and reduced sleep over 4 weeks. A neurological examination revealed opsoclonus, irritability, generalized tremulousness, and fragmentary myoclonus. Neuroimaging was suggestive of TBM. A cerebrospinal fluid (CSF) analysis indicated lymphocytic pleocytosis with positive CSF cartridge-based nucleic acid amplification test results for tuberculosis. The patient was treated with methylprednisolone pulse therapy, intravenous immunoglobulins, and anti-tuberculous therapy (ATT). Significant symptom improvement was observed within 2 weeks. This case underscores a rare association between OMAS and TBM, demonstrating that tuberculosis can trigger OMAS through autoimmune mechanisms. A timely diagnosis and treatment with ATT and immunotherapy can lead to substantial recovery.

2025-04-01·Journal of Neurology

Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with multiple autoimmune comorbidities—a case report

Letter

作者: Nilsson, Anna Christine ; Sørensen, Nina Vindegaard ; Stenør, Christian Midtgaard ; Dos, Al-Hasan Hussein